35 studies found for:    mononucleosis
Show Display Options
RSS Create an RSS feed from your search for:
mononucleosis
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
Condition: Infectious Mononucleosis
Interventions: Drug: Valomaciclovir;   Drug: placebo
2 Completed Controlled Trial of Valacyclovir in Infectious Mononucleosis
Condition: Infectious Mononucleosis
Intervention: Drug: valacyclovir
3 Completed Acupuncture for Infectious Mononucleosis Trial
Condition: Infectious Mononucleosis
Interventions: Procedure: traditional Chinese acupuncture;   Other: standard medical care
4 Completed Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals’ EBV (Epstein Barr Virus) Vaccine (268664).
Condition: Epstein Barr Virus (EBV) Infection
Intervention: Biological: EBV vaccine (268664)
5 Recruiting Genetic Studies of Chronic Active Epstein-Barr Disease
Condition: Epstein-Barr Virus Infections
Intervention:
6 Completed Genetic Studies of X-linked Lymphoproliferative Disease
Conditions: X-Linked Lymphoproliferative Disease;   Lymphoproliferative Disease;   Genetic Diseases, X-Linked
Intervention:
7 Recruiting Specific Cytotoxic T-Lymphocytes, EBV-positive Lymphoma, GRALE
Conditions: Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Lymphoproliferative Disease;   Lymphoma
Interventions: Biological: LMP, BARF1 & EBNA1 specific CTLs: A;   Biological: LMP, BARF1 & EBNA1 specific CTLs : B
8 Completed Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus
Conditions: Epstein Barr Virus Infection;   Healthy
Intervention:
9 Recruiting Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Biological: Antigen Escalation Stage;   Biological: Dose escalation study of T cells
10 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
11 Recruiting ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus
Condition: Viral Infection
Intervention: Biological: Multi-virus-specific cytotoxic T lymphocytes
12 Active, not recruiting Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma
Condition: Indolent Non-Hodgkin's Lymphoma
Intervention:
13 Recruiting A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Conditions: Congenital Cytomegalovirus Infection;   Maternal Cytomegalovirus Infection
Intervention: Drug: CMV hyperimmune globulin
14 Recruiting HIV Indicator Diseases Across Europe Study
Condition: HIV
Intervention:
15 Terminated Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease
Conditions: Hodgkin Disease;   Non-Hodgkins Lymphoma
Intervention: Drug: Infusion of EBV Specific Cytotoxic T-Lymphocytes
16 Active, not recruiting Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL
Conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma;   Epstein-Barr Virus-Related Non-Hodgkin Lymphoma;   EBV Positive Plasma Cell Neoplasm
Intervention: Genetic: Injection of EBV Specific CTLs
17 Completed T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
Condition: Head and Neck Cancer
Intervention: Biological: autologous EBV specific CTLs
18 Not yet recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific CTLs
19 Terminated Vaccination With Tetanus and KLH to Assess Immune Responses.
Condition: Cancer
Interventions: Biological: Intracel KLH Vaccine;   Biological: Biosyn KLH;   Drug: Montanide ISA51;   Biological: Tetanus toxoid
20 Terminated Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
Conditions: Hodgkins Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES;   Genetic: LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES

Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results
Indicates status has not been verified in more than two years